IN2014DN01605A - - Google Patents
Info
- Publication number
- IN2014DN01605A IN2014DN01605A IN1605DEN2014A IN2014DN01605A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A IN 1605DEN2014 A IN1605DEN2014 A IN 1605DEN2014A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A
- Authority
- IN
- India
- Prior art keywords
- gene
- ret
- fusion
- cases
- mutation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G01N33/5752—
-
- G01N33/57557—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171256 | 2011-08-04 | ||
| PCT/JP2012/069799 WO2013018882A1 (ja) | 2011-08-04 | 2012-08-03 | Kif5b遺伝子とret遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01605A true IN2014DN01605A (enExample) | 2015-05-15 |
Family
ID=47629396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1605DEN2014 IN2014DN01605A (enExample) | 2011-08-04 | 2012-08-03 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9216172B2 (enExample) |
| EP (1) | EP2740742B1 (enExample) |
| JP (1) | JP6032616B2 (enExample) |
| KR (1) | KR20140047138A (enExample) |
| CN (1) | CN103764676A (enExample) |
| CA (1) | CA2848369A1 (enExample) |
| IN (1) | IN2014DN01605A (enExample) |
| WO (1) | WO2013018882A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3205654T3 (pl) | 2010-05-20 | 2019-08-30 | Array Biopharma, Inc. | Związki makrocykliczne jako inhibitory kinazy TRK |
| EP2620497B1 (en) | 2010-09-02 | 2017-10-11 | Kurume University | Method for producing circular dna formed from single-molecule dna |
| AU2012298884B2 (en) | 2011-08-23 | 2017-11-16 | Foundation Medicine, Inc. | Novel KIF5B-RET fusion molecules and uses thereof |
| CN103890175B (zh) | 2011-08-31 | 2015-12-09 | 学校法人久留米大学 | 在dna分子的环化中仅选择由单分子形成的环化dna的方法 |
| US10023855B2 (en) * | 2011-10-31 | 2018-07-17 | Macrogen, Inc. | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
| LT2902029T (lt) | 2012-09-25 | 2018-10-25 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitorius |
| CA3009552A1 (en) * | 2013-03-15 | 2014-09-18 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| EP3037547A1 (en) | 2013-08-20 | 2016-06-29 | National Cancer Center | New fusion gene detected in lung cancer |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| EA038890B1 (ru) | 2015-11-02 | 2021-11-03 | Блюпринт Медсинс Корпорейшн | Ингибиторы ret |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| CN110191705A (zh) | 2016-12-01 | 2019-08-30 | 亚尼塔公司 | 治疗癌症的方法 |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP2020519672A (ja) | 2017-05-15 | 2020-07-02 | ブループリント メディシンズ コーポレイション | RET阻害剤とmTORC1阻害剤との組合せ及び異常なRET活性によって媒介されるがんを処置するためのその使用 |
| MY201941A (en) * | 2017-08-21 | 2024-03-25 | Taiho Pharmaceutical Co Ltd | Fusion protein of dctn1 protein with ret protein |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019195471A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| CN112703014A (zh) | 2018-08-10 | 2021-04-23 | 缆图药品公司 | Egfr突变型癌症的治疗 |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN111154872A (zh) * | 2019-12-31 | 2020-05-15 | 浙江大学 | 用于检测肺癌驱动性基因突变的探针及试剂盒 |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN111909987A (zh) * | 2020-07-31 | 2020-11-10 | 浙江科途医学科技有限公司 | 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测系统 |
| CN113637709B (zh) * | 2021-08-14 | 2023-01-17 | 中国农业科学院兰州兽医研究所 | Kif5b基因作为靶点在抑制口蹄疫病毒复制中的应用 |
| JP2023177142A (ja) * | 2022-06-01 | 2023-12-13 | 国立研究開発法人国立がん研究センター | Retキナーゼ阻害剤によるがん治療の有効性を判定する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598052B2 (en) * | 2005-10-11 | 2009-10-06 | The Regents Of The University Of Michigan | Expression profile of thyroid cancer |
| CA2624221A1 (en) | 2005-10-24 | 2007-05-03 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
| EP1920767A1 (en) | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| JP2010509289A (ja) | 2006-11-09 | 2010-03-25 | アボット ゲーエムベーハー ウント コンパニー カーゲー | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 |
| WO2010000012A1 (en) * | 2008-07-03 | 2010-01-07 | The University Of Sydney | Method for preventing transport of a neurotropic virus |
| JPWO2012014795A1 (ja) * | 2010-07-26 | 2013-09-12 | アステラス製薬株式会社 | 新規ret融合体の検出法 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
-
2012
- 2012-08-03 IN IN1605DEN2014 patent/IN2014DN01605A/en unknown
- 2012-08-03 CN CN201280038650.4A patent/CN103764676A/zh not_active Withdrawn
- 2012-08-03 JP JP2013526964A patent/JP6032616B2/ja active Active
- 2012-08-03 KR KR20147004610A patent/KR20140047138A/ko not_active Withdrawn
- 2012-08-03 EP EP12820601.8A patent/EP2740742B1/en active Active
- 2012-08-03 US US14/236,900 patent/US9216172B2/en active Active
- 2012-08-03 CA CA 2848369 patent/CA2848369A1/en not_active Abandoned
- 2012-08-03 WO PCT/JP2012/069799 patent/WO2013018882A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20140221404A1 (en) | 2014-08-07 |
| US9216172B2 (en) | 2015-12-22 |
| EP2740742A1 (en) | 2014-06-11 |
| CN103764676A (zh) | 2014-04-30 |
| JP6032616B2 (ja) | 2016-11-30 |
| JPWO2013018882A1 (ja) | 2015-03-05 |
| WO2013018882A1 (ja) | 2013-02-07 |
| EP2740742B1 (en) | 2018-03-14 |
| CA2848369A1 (en) | 2013-02-07 |
| EP2740742A4 (en) | 2015-06-17 |
| KR20140047138A (ko) | 2014-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01605A (enExample) | ||
| MX2012003770A (es) | Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia. | |
| GB201103062D0 (en) | Method | |
| EA201792663A1 (ru) | Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr | |
| PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| PH12018500317B1 (en) | Salts of an lsd1 inhibitor | |
| SG10201811175WA (en) | Method for treating cancer using a combination of chk1 and atr inhibitors | |
| NZ601606A (en) | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors | |
| MX2022015737A (es) | Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm). | |
| EA201500362A1 (ru) | Ингибиторы rho-киназы | |
| EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| PH12013502623A1 (en) | Metalloenzyme inhibitor compounds | |
| PH12013502622A1 (en) | Metalloenzyme inhibitor compounds | |
| HK1259386A1 (zh) | 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途 | |
| IN2014DN06164A (enExample) | ||
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| CA2864161A1 (en) | Inhibition of the glycine cleavage system for treatment of cancer | |
| EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
| EA201792344A1 (ru) | Ген мужской стерильности пшеницы wms и его промотор специфичной для пыльника экспрессии и их применение | |
| MX2016013600A (es) | Método para tratar adenocarcinoma de pulmón. | |
| MX371119B (es) | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. | |
| MY169029A (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof |